Biocon Limited lists 17,12,79,553 new equity shares issued at Rs. 405.78 per share through preferential allotment via share swap, with trading commencing January 12, 2026.
Impact
High
Severity
Medium
Justification
Major capital event involving over 171 million new shares representing significant dilution; large-scale preferential allotment to non-promoters with 6-month lock-in period
NSE admits commercial paper securities of Biocon Limited and Kotak Securities Limited to trading on the debt market segment effective January 05, 2026.
Impact
Low
Severity
Low
Justification
Routine listing notification for commercial paper securities with no broader market implications or regulatory changes
BSE demat auction settlement for delivery shortages across 130 scrips with quantities ranging from 1 to 50,000 shares.
Impact
Low
Severity
Low
Justification
Routine demat auction for settlement of delivery shortages; standard market operations procedure affecting specific scrips with limited market-wide impact
Updated position limits for derivatives trading including MWPL, client limits, proprietary limits, TM limits, FPI and MF limits across multiple securities.
Impact
High
Severity
Medium
Justification
Critical reference document for F&O traders, brokers, FPIs and mutual funds defining maximum permissible positions across client, proprietary, and institutional categories for 42+ actively traded securities
BSE Demat Auction listing 79 scrips scheduled for auction settlement on December 5, 2025, covering various securities across different companies with specified quantities.
Impact
Medium
Severity
Medium
Justification
Routine demat auction affecting 79 scrips with varying quantities; impacts shareholders who failed to deliver securities in previous settlements and need to fulfill obligations through auction mechanism